SLDB

Announcements

Nothing here yet

Daily updates

Nothing here yet

FDA designations

Nothing here yet

News

• Solid Biosciences doses first participant in Phase 3 IMPACT DUCHENNE trial of SGT-003May 7, 2026
• Solid Biosciences received European Commission Orphan Drug Designation for SGT-003 in Duchenne muscular dystrophyApr 28, 2026
• Solid Biosciences reported positive interim clinical data from the Phase 1/2 INSPIRE DUCHENNE trialMar 12, 2026
• Solid Biosciences received positive FDA feedback from a Type C meeting regarding SGT-003 gene therapy for Duchenne muscular dystrophyFeb 9, 2026
• Solid Biosciences received FDA Orphan Drug Designation for SGT-212 in Friedreich's AtaxiaJan 13, 2026